Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Double-blind Study of LY2216684 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.

Next Previous
Trial Profile

A Randomized, Placebo-controlled, Double-blind Study of LY2216684 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edivoxetine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 27 Sep 2016 Results of pooled analysis from 4 adjunctive treatment trials and 1 monotherapy trial (n=2561) published in the Journal of Clinical Psychiatry.
  • 01 Mar 2016 Results of pooled analysis of this and other 2 trials (NCT01187407 and NCT01185340) published in the Journal of Clinical Psychiatry
  • 05 Dec 2013 Top-line results published in an Eli Lilly media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top